We named our company Espero because it means hope. And that’s what we seek to provide everyone who takes our innovative cardiovascular medicines. Hope for improved health and hope for a better tomorrow.
Espero is a biopharmaceutical company focusing on the late-stage development and commercialization of medicines to treat cardiovascular diseases, the leading cause of death worldwide. Recently, Espero merged with Armetheon, Inc., a privately-held, specialty pharmaceutical company developing innovative medicines, initially in thrombosis (tecarfarin) and cardiac arrhythmias (budiodarone). The Company also markets and distributes three in-market standard of care cardiovascular drugs: GoNitroTM (nitroglycerin) sublingual powder (antianginal), Durlaza® (aspirin) Extended Release Capsules, and Nitrolingual® Pumpspray (antianginal).